Dose or time? Comparing early prediction of intermittent theta-burst stimulation response across accelerated and daily protocols for depression
Open Access
- 1 June 2026
- journal article
- Published by Springer Nature in European Archives of Psychiatry and Clinical Neuroscience
- Vol. 276 (5) , 2537-2546
Abstract
Objective: To compare early response prediction across accelerated and standard intermittent theta-burst stimulation (iTBS) protocols for major depressive disorder, examining whether predictive performance differs when assessments are matched by cumulative pulse exposure versus calendar time. Methods: Pooled analysis of two prospective iTBS trials conducted at Instituto de Psiquiatria, Hospital das Clínicas, Universidade de São Paulo: the open-label BRAEN-MAP trial (once-daily; N = 65; 20 sessions over 4 weeks) and the active arm of the triple-blind, sham-controlled randomized TTT trial (accelerated; N = 50; 45 sessions over 3 weeks). Assessments were matched by cumulative pulses (18,000 pulses), calendar time (Weeks 1 and 2), or session count (15 sessions). Early improvement was defined as ≥ 20% HDRS-17 reduction. Positive predictive values (PPV) and negative predictive values (NPV) were compared using bootstrap resampling. Results: Response rates did not differ between trials (BRAEN-MAP: 55.4%; TTT: 54.0%; p = 0.95). For response prediction, PPV ranged from 66.7% to 75.0% across protocol-timepoint combinations, with no significant differences between protocols at pulse-matched (66.7% vs. 68.9%, p = 0.84), time-matched, or session-matched (66.7% vs. 68.8%, p = 0.86) comparisons (all bootstrap p > 0.43). NPV for non-response prediction ranged from 69.0% to 82.4%, also without significant between-protocol differences. Trajectory analyses demonstrated that early improvers maintained steeper improvement through endpoint. Conclusion: Early symptom improvement predicts iTBS response consistently across accelerated and standard protocols regardless of whether assessments are matched by cumulative pulses, calendar time, or number of sessions. These preliminary findings support early response assessment as a protocol-independent clinical tool, though the accuracy levels observed (PPV 67–75%) are insufficient to justify treatment discontinuation and may be most useful within adaptive, measurement-based care frameworks.Keywords
Funding Information
- Conselho Nacional de Desenvolvimento Científico e Tecnológico
- Fundação de Amparo à Pesquisa do Estado de São Paulo (21/10827-6)
This publication has 18 references indexed in Scilit:
- Accelerated Theta-Burst Stimulation for Treatment-Resistant DepressionJAMA Psychiatry, 2025
- When to hold and when to fold: Early prediction of nonresponse to transcranial magnetic stimulation in major depressive disorderBrain Stimulation, 2024
- Repetitive transcranial magnetic stimulation: Course and early prediction of response in depressionJournal of Psychiatric Research, 2022
- Absence of early mood improvement as a robust predictor of rTMS nonresponse in major depressive disorderDepression and Anxiety, 2022
- Strategies for augmentation of high-frequency left-sided repetitive transcranial magnetic stimulation treatment of major depressive disorderJournal of Affective Disorders, 2020
- Can early treatment response serve as a predictor of antidepressant outcome of repetitive Transcranial Magnetic Stimulation?Brain Stimulation, 2020
- A systematic review and meta-analysis on placebo response to repetitive transcranial magnetic stimulation for depression trialsProgress in Neuro-Psychopharmacology and Biological Psychiatry, 2018
- Early symptom improvement at 10 sessions as a predictor of rTMS treatment outcome in major depressionBrain Stimulation, 2018
- Concordance Between BeamF3 and MRI-neuronavigated Target Sites for Repetitive Transcranial Magnetic Stimulation of the Left Dorsolateral Prefrontal CortexBrain Stimulation, 2015
- An efficient and accurate new method for locating the F3 position for prefrontal TMS applicationsBrain Stimulation, 2009